VANCOUVER, BC/ ACCESS Newswire/ April 23, 2025/ BioNxt Solutions Inc., a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its ...

Adocia receives a $10 million milestone payment from Lilly after successful completion of this clinical pilot study. December 11, 2015 01:52 AM Eastern Standard Time LYON & INDIANAPOLIS ...

This study was designed to investigate, in accordance with international regulatory guidelines, the bioequivalence of two omeprazole products following single- and multiple-dose administration, as ...

Bioequivalence Study of Three Ibuprofen Formulations After Single Dose Administration in Healthy Volunteers. ... (Clinical trial report BCBe/02/Ibu-BV-001) and data from Blume and Mutschler.

FDA now recommends only one study to show bioequivalence for certain oral drug products - FDA also revises several hundred product specific guidances to align with ICH M13A BE standards ...

REDWOOD CITY, Calif., Aug. 28, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today reported topline results from the first of three ongoing pharmacokinetic bioequivalence ...

On April 10, 2023, Celltrion confirmed the bioequivalence of CT-P39 to treat allergic ... P39 Against Xolair In Interim Results Of Phase 3 Study. ... Public Benefit Report; ...

NORTHVALE, N.J., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and ...

BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party ...

VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...

VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug ...